{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:34:14Z","timestamp":1792600454445,"version":"4.5.0"},"reference-count":162,"publisher":"Harborside Press, LLC","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:p>The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pediatric Acute Lymphoblastic Leukemia (ALL) were developed as a result of meetings convened by a multidisciplinary panel of pediatric ALL experts, with the goal of providing recommendations on standard treatment approaches based on current evidence. The NCCN Guidelines for pediatric ALL focus on risk assessment and stratification of risk-adapted therapy; treatment strategies for <jats:italic>BCR::ABL1<\/jats:italic> (Philadelphia chromosome [Ph])-negative and <jats:italic>BCR::ABL1<\/jats:italic>-positive B-cell lineage, T-cell lineage, and infant ALL; and supportive care considerations. This selection from the NCCN Guidelines for pediatric ALL focuses on the diagnosis of and management of pediatric T-ALL.<\/jats:p>","DOI":"10.6004\/jnccn.2025.0006","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T16:04:25Z","timestamp":1739376265000},"page":"41-62","source":"Crossref","is-referenced-by-count":40,"title":["Pediatric Acute Lymphoblastic Leukemia, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology"],"prefix":"10.6004","volume":"23","author":[{"given":"Hiroto","family":"Inaba","sequence":"first","affiliation":[{"name":"St. Jude Children\u2019s Research Hospital\/The University of Tennessee Health Science Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Teachey","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center at the University of Pennsylvania\/Children\u2019s Hospital of Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Annesley","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center\/Seattle Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Batra","sequence":"additional","affiliation":[{"name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center\/Riley Children\u2019s Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Beck","sequence":"additional","affiliation":[{"name":"Fred & Pamela Buffett Cancer Center\/Children\u2019s Hospital & Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Colace","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute\/Nationwide Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy","family":"Cooper","sequence":"additional","affiliation":[{"name":"Johns Hopkins Kimmel Cancer Center\/Johns Hopkins Children\u2019s Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Dallas","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute\/University Hospitals Rainbow Babies & Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satiro De","family":"Oliveira","sequence":"additional","affiliation":[{"name":"UCLA Jonsson Comprehensive Cancer Center\/UCLA Mattel Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Kelly","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center\/Roswell Park Oishei Children\u2019s Cancer and Blood Disorders Program"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Kitko","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center\/Monroe Carell Jr. Children\u2019s Hospital at Vanderbilt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"Kohorst","sequence":"additional","affiliation":[{"name":"Mayo Clinic Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Kutny","sequence":"additional","affiliation":[{"name":"O\u2019Neal Comprehensive Cancer Center at UAB\/Children\u2019s of Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman","family":"Lacayo","sequence":"additional","affiliation":[{"name":"Stanford Cancer Institute\/Lucile Packard Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Lee-Miller","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center\/American Family Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Ludwig","sequence":"additional","affiliation":[{"name":"UT Southwestern Simmons Comprehensive Cancer Center\/Children\u2019s Medical Center Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Madden","sequence":"additional","affiliation":[{"name":"UC Davis Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Maloney","sequence":"additional","affiliation":[{"name":"University of Colorado Cancer Center\/Children\u2019s Hospital Colorado"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Mangum","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute at the University of Utah\/Primary Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Massaro","sequence":"additional","affiliation":[{"name":"Yale Cancer Center\/Smilow Cancer Hospital\/Yale New Haven Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"McCall","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry","family":"Morocco","sequence":"additional","affiliation":[{"name":"The UChicago Medicine Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Muller","sequence":"additional","affiliation":[{"name":"St. Jude Children\u2019s Research Hospital\/The University of Tennessee Health Science Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Murphy","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Nardi","sequence":"additional","affiliation":[{"name":"Mass General Cancer Center\/Dana-Farber\/Boston Children\u2019s Cancer and Blood Disorders Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Rossoff","sequence":"additional","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University\/Ann & Robert H. Lurie Children\u2019s Hospital of Chicago"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Schuettpelz","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine\/St. Louis Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijal","family":"Shah","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Sun","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute\/Duke Children\u2019s Hospital & Health Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Wong","sequence":"additional","affiliation":[{"name":"UC San Diego Moores Cancer Center\/Rady Children\u2019s Hospital-San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Yanik","sequence":"additional","affiliation":[{"name":"University of Michigan Rogel Cancer Center\/C.S. Mott Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajibola","family":"Awotiwon","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Stehman","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","article-title":"SEER cancer statistics review, 1975-2015: Leukemia, annual incidence rates (acute lymphocytic leukemia)","unstructured":"National Cancer Institute. SEER cancer statistics review, 1975-2015: Leukemia, annual incidence rates (acute lymphocytic leukemia). Accessed January 24, 2023. Available at: https:\/\/seer.cancer.gov\/csr\/1975_2015\/"},{"key":"B2","series-title":"CA Cancer J Clin","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel RL","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin 2024;74:12\u201349."},{"key":"B3","series-title":"MedGenMed","first-page":"23","article-title":"Topics in pediatric leukemia\u2013acute lymphoblastic leukemia","volume":"7","author":"Esparza SD","year":"2005","unstructured":"Esparza SD, Sakamoto KM. Topics in pediatric leukemia\u2013acute lymphoblastic leukemia. MedGenMed 2005;7:23."},{"key":"B4","series-title":"Mayo Clin Proc","first-page":"1517","article-title":"Adult acute lymphoblastic leukemia","volume":"80","author":"Jabbour EJ","year":"2005","unstructured":"Jabbour EJ, Faderl S, Kantarjian HM. Adult acute lymphoblastic leukemia. Mayo Clin Proc 2005;80:1517\u20131527."},{"key":"B5","article-title":"SEER cancer statistics review, 1975-2015: Overview, median age at diagnosis","unstructured":"National Cancer Institute. SEER cancer statistics review, 1975-2015: Overview, median age at diagnosis. Accessed January 24, 2023. Available at: https:\/\/seer.cancer.gov\/csr\/1975_2015\/"},{"key":"B6","article-title":"SEER cancer statistics review, 1975-2015: Overview, age distribution of incidence cases by site","unstructured":"National Cancer Institute. SEER cancer statistics review, 1975-2015: Overview, age distribution of incidence cases by site. Accessed January 24, 2023. Available at: https:\/\/seer.cancer.gov\/csr\/1975_2015\/"},{"key":"B7","series-title":"Blood","first-page":"159","article-title":"How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children","volume":"135","author":"Teachey DT","year":"2020","unstructured":"Teachey DT, O\u2019Connor D. How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children. Blood 2020;135:159\u2013166."},{"key":"B8","series-title":"Lancet Oncol","first-page":"e142","article-title":"Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia","volume":"20","author":"Teachey DT","year":"2019","unstructured":"Teachey DT, Pui CH. Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia. Lancet Oncol 2019;20:e142\u2013154."},{"key":"B9","series-title":"Blood","article-title":"Classification and risk stratification in T-lineage acute lymphoblastic leukemia","author":"Polonen P","unstructured":"Polonen P, Mullighan CG, Teachey DT. Classification and risk stratification in T-lineage acute lymphoblastic leukemia. Blood. Published online October 2, 2024. doi:10.1182\/blood.2023022920"},{"key":"B10","series-title":"Sci Rep","first-page":"4227","article-title":"Survival improvement by decade of patients aged 0-14 years with acute lymphoblastic leukemia: a SEER analysis","volume":"4","author":"Ma H","year":"2014","unstructured":"Ma H, Sun H, Sun X. Survival improvement by decade of patients aged 0-14 years with acute lymphoblastic leukemia: a SEER analysis. Sci Rep 2014;4:4227."},{"key":"B11","series-title":"Blood","first-page":"1408","article-title":"Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century","volume":"113","author":"Pulte D","year":"2009","unstructured":"Pulte D, Gondos A, Brenner H. Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood 2009;113:1408\u20131411."},{"key":"B12","series-title":"Blood","first-page":"1878","article-title":"Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis","volume":"129","author":"Geyer MB","year":"2017","unstructured":"Geyer MB, Hsu M, Devlin SM,  Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis. Blood 2017;129:1878\u20131881."},{"key":"B13","series-title":"PLoS One","first-page":"e85554","article-title":"Survival of adults with acute lymphoblastic leukemia in Germany and the United States","volume":"9","author":"Pulte D","year":"2014","unstructured":"Pulte D, Jansen L, Gondos A,  Survival of adults with acute lymphoblastic leukemia in Germany and the United States. PLoS One 2014;9:e85554."},{"key":"B14","series-title":"Br J Haematol","first-page":"463","article-title":"Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII\/ECOG2993 trial","volume":"157","author":"Sive JI","year":"2012","unstructured":"Sive JI, Buck G, Fielding A,  Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII\/ECOG2993 trial. Br J Haematol 2012;157:463\u2013471."},{"key":"B15","series-title":"Blood","first-page":"660","article-title":"Comorbidities are frequent in older patients with de novo acute lymphoblastic leukemia (ALL) and correlate with induction mortality: analysis of more than 1200 patients from GMALL data bases","volume":"132","author":"Wermann WK","year":"2018","unstructured":"Wermann WK, Viardot A, Kayser S,  Comorbidities are frequent in older patients with de novo acute lymphoblastic leukemia (ALL) and correlate with induction mortality: analysis of more than 1200 patients from GMALL data bases. Blood 2018;132:660."},{"key":"B16","series-title":"CA Cancer J Clin","first-page":"443","article-title":"Cancer statistics for adolescents and young adults, 2020","volume":"70","author":"Miller KD","year":"2020","unstructured":"Miller KD, Fidler-Benaoudia M, Keegan TH,  Cancer statistics for adolescents and young adults, 2020. CA Cancer J Clin 2020;70:443\u2013459."},{"key":"B17","series-title":"J Clin Oncol","first-page":"2246","article-title":"Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the Interfant-06 protocol: results from an international phase III randomized study","volume":"37","author":"Pieters R","year":"2019","unstructured":"Pieters R, De Lorenzo P, Ancliffe P,  Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the Interfant-06 protocol: results from an international phase III randomized study. J Clin Oncol 2019;37:2246\u20132256."},{"key":"B18","series-title":"N Engl J Med","first-page":"1572","article-title":"Blinatumomab added to chemotherapy in infant lymphoblastic leukemia","volume":"388","author":"van der Sluis IM","year":"2023","unstructured":"van der Sluis IM, de Lorenzo P, Kotecha RS,  Blinatumomab added to chemotherapy in infant lymphoblastic leukemia. N Engl J Med 2023;388:1572\u20131581."},{"key":"B19","series-title":"Hematology Am Soc Hematol Educ Program","first-page":"21","article-title":"Adolescents and young adults with acute lymphoblastic leukemia","volume":"2010","author":"Stock W.","year":"2010","unstructured":"Stock W. Adolescents and young adults with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2010;2010:21\u201329."},{"key":"B20","series-title":"Cancer","first-page":"1165","article-title":"Adult acute lymphoblastic leukemia: concepts and strategies","volume":"116","author":"Faderl S","year":"2010","unstructured":"Faderl S, O\u2019Brien S, Pui CH,  Adult acute lymphoblastic leukemia: concepts and strategies. Cancer 2010;116:1165\u20131176."},{"key":"B21","series-title":"BMJ Case Rep","article-title":"Initial presentation of childhood leukaemia with facial palsy: three case reports","author":"Karimi M","unstructured":"Karimi M, Cohan N, Zareifar S,  Initial presentation of childhood leukaemia with facial palsy: three case reports. BMJ Case Rep. Published online December 9, 2009. doi:10.1136\/bcr.10.2008.1046"},{"key":"B22","series-title":"Pediatr Blood Cancer","first-page":"426","article-title":"Numb chin syndrome as initial manifestation in a child with acute lymphoblastic leukemia","volume":"51","author":"Kraigher-Krainer E","year":"2008","unstructured":"Kraigher-Krainer E, Lackner H, Sovinz P,  Numb chin syndrome as initial manifestation in a child with acute lymphoblastic leukemia. Pediatr Blood Cancer 2008;51:426\u2013428."},{"key":"B23","series-title":"Leukemia","first-page":"1720","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio R","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I,  The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 2022;36:1720\u20131748."},{"key":"B24","series-title":"Leukemia","first-page":"1567","article-title":"Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias","volume":"19","author":"Amin HM","year":"2005","unstructured":"Amin HM, Yang Y, Shen Y,  Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias. Leukemia 2005;19:1567\u20131572."},{"key":"B25","series-title":"Am J Clin Pathol","first-page":"733","article-title":"Use of peripheral blood blasts vs bone marrow blasts for diagnosis of acute leukemia","volume":"111","author":"Weinkauff R","year":"1999","unstructured":"Weinkauff R, Estey EH, Starostik P,  Use of peripheral blood blasts vs bone marrow blasts for diagnosis of acute leukemia. Am J Clin Pathol 1999;111:733\u2013740."},{"key":"B26","series-title":"Eur J Haematol","first-page":"447","article-title":"Lymphoblastic lymphoma: an updated review on biology, diagnosis, and treatment","volume":"96","author":"Bassan R","year":"2016","unstructured":"Bassan R, Maino E, Cortelazzo S. Lymphoblastic lymphoma: an updated review on biology, diagnosis, and treatment. Eur J Haematol 2016;96:447\u2013460."},{"key":"B27","series-title":"Crit Rev Oncol Hematol","first-page":"304","article-title":"Lymphoblastic lymphoma","volume":"113","author":"Cortelazzo S","year":"2017","unstructured":"Cortelazzo S, Ferreri A, Hoelzer D, Ponzoni M. Lymphoblastic lymphoma. Crit Rev Oncol Hematol 2017;113:304\u2013317."},{"key":"B28","series-title":"J Clin Oncol","first-page":"532","article-title":"Modern therapy of acute lymphoblastic leukemia","volume":"29","author":"Bassan R","year":"2011","unstructured":"Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol 2011;29:532\u2013543."},{"key":"B29","series-title":"Pediatr Clin North Am","first-page":"61","article-title":"Treatment of pediatric acute lymphoblastic leukemia","volume":"62","author":"Cooper SL","year":"2015","unstructured":"Cooper SL, Brown PA. Treatment of pediatric acute lymphoblastic leukemia. Pediatr Clin North Am 2015;62:61\u201373."},{"key":"B30","first-page":"209","article-title":"T-lymphoblastic leukaemia\/lymphoma","author":"Borowitz MJ","year":"2017","unstructured":"Borowitz MJ, Chan JKC, Bene MC, Arber DA. T-lymphoblastic leukaemia\/lymphoma. In: Swerdlow SH, Campo E, Harris NL, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edition. Lyon, France: IARC; 2017:209\u2013212."},{"key":"B31","series-title":"N Engl J Med","first-page":"1535","article-title":"Acute lymphoblastic leukemia","volume":"350","author":"Pui CH","year":"2004","unstructured":"Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med 2004;350:1535\u20131548."},{"key":"B32","series-title":"Crit Rev Oncol Hematol","first-page":"223","article-title":"Adult acute lymphoblastic leukaemia","volume":"50","author":"Bassan R","year":"2004","unstructured":"Bassan R, Gatta G, Tondini C, Willemze R. Adult acute lymphoblastic leukaemia. Crit Rev Oncol Hematol 2004;50:223\u2013261."},{"key":"B33","series-title":"Leukemia","first-page":"1783","article-title":"Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL)","volume":"9","author":"Bene MC","year":"1995","unstructured":"Bene MC, Castoldi G, Knapp W,  Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995;9:1783\u20131786."},{"key":"B34","series-title":"Lancet Oncol","first-page":"147","article-title":"Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia","volume":"10","author":"Coustan-Smith E","year":"2009","unstructured":"Coustan-Smith E, Mullighan CG, Onciu M,  Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009;10:147\u2013156."},{"key":"B35","series-title":"Br J Haematol","first-page":"358","article-title":"Clinical significance of early T-cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children\u2019s Cancer Study Group Study L99-15","volume":"156","author":"Inukai T","year":"2012","unstructured":"Inukai T, Kiyokawa N, Campana D,  Clinical significance of early T-cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children\u2019s Cancer Study Group Study L99-15. Br J Haematol 2012;156:358\u2013365."},{"key":"B36","series-title":"Front Med","first-page":"416","article-title":"Early T-cell precursor leukemia: a subtype of high risk childhood acute lymphoblastic leukemia","volume":"6","author":"Ma M","year":"2012","unstructured":"Ma M, Wang X, Tang J,  Early T-cell precursor leukemia: a subtype of high risk childhood acute lymphoblastic leukemia. Front Med 2012;6:416\u2013420."},{"key":"B37","series-title":"Br J Haematol","first-page":"421","article-title":"Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003","volume":"166","author":"Patrick K","year":"2014","unstructured":"Patrick K, Wade R, Goulden N,  Outcome for children and young people with Early T-cell precursor acute lymphoblastic leukaemia treated on a contemporary protocol, UKALL 2003. Br J Haematol 2014;166:421\u2013424."},{"key":"B38","series-title":"Hematology Am Soc Hematol Educ Program","first-page":"580","article-title":"T-cell acute lymphoblastic leukemia","volume":"2016","author":"Raetz EA","year":"2016","unstructured":"Raetz EA, Teachey DT. T-cell acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2016;2016:580\u2013588."},{"key":"B39","series-title":"Blood","first-page":"2069","article-title":"Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children\u2019s Oncology Group study","volume":"142","author":"Wood BL","year":"2023","unstructured":"Wood BL, Devidas M, Summers RJ,  Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children\u2019s Oncology Group study. Blood 2023;142:2069\u20132078."},{"key":"B40","series-title":"Nat Rev Immunol","first-page":"380","article-title":"Molecular pathogenesis of T-cell leukaemia and lymphoma","volume":"8","author":"Aifantis I","year":"2008","unstructured":"Aifantis I, Raetz E, Buonamici S. Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol 2008;8:380\u2013390."},{"key":"B41","series-title":"Hematology Am Soc Hematol Educ Program","first-page":"389","article-title":"The molecular genetic makeup of acute lymphoblastic leukemia","volume":"2012","author":"Mullighan CG.","year":"2012","unstructured":"Mullighan CG. The molecular genetic makeup of acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2012;2012:389\u2013396."},{"key":"B42","series-title":"Front Pediatr","first-page":"54","article-title":"The challenge of targeting notch in hematologic malignancies","volume":"2","author":"Hernandez Tejada FN","year":"2014","unstructured":"Hernandez Tejada FN, Galvez Silva JR, Zweidler-McKay PA. The challenge of targeting notch in hematologic malignancies. Front Pediatr 2014;2:54."},{"key":"B43","series-title":"J Exp Med","first-page":"1813","article-title":"FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors","volume":"204","author":"O\u2019Neil J","year":"2007","unstructured":"O\u2019Neil J, Grim J, Strack P,  FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med 2007;204:1813\u20131824."},{"key":"B44","series-title":"Science","first-page":"269","article-title":"Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia","volume":"306","author":"Weng AP","year":"2004","unstructured":"Weng AP, Ferrando AA, Lee W,  Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004;306:269\u2013271."},{"key":"B45","series-title":"Blood","first-page":"3918","article-title":"NOTCH1\/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study","volume":"113","author":"Asnafi V","year":"2009","unstructured":"Asnafi V, Buzyn A, Le Noir S,  NOTCH1\/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. Blood 2009;113:3918\u20133924."},{"key":"B46","series-title":"Blood","first-page":"1151","article-title":"Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia","volume":"108","author":"Breit S","year":"2006","unstructured":"Breit S, Stanulla M, Flohr T,  Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. Blood 2006;108:1151\u20131157."},{"key":"B47","series-title":"Leukemia","first-page":"2023","article-title":"NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951","volume":"24","author":"Clappier E","year":"2010","unstructured":"Clappier E, Collette S, Grardel N,  NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951. Leukemia 2010;24:2023\u20132031."},{"key":"B48","series-title":"J Clin Oncol","first-page":"4333","article-title":"Toward a NOTCH1\/FBXW7\/RAS\/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study","volume":"31","author":"Trinquand A","year":"2013","unstructured":"Trinquand A, Tanguy-Schmidt A, Ben Abdelali R,  Toward a NOTCH1\/FBXW7\/RAS\/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. J Clin Oncol 2013;31:4333\u20134342."},{"key":"B49","series-title":"Leukemia","first-page":"39","article-title":"Impact of PTEN abnormalities on outcome in pediatric patients with T-cell acute lymphoblastic leukemia treated on the MRC UKALL2003 trial","volume":"30","author":"Jenkinson S","year":"2016","unstructured":"Jenkinson S, Kirkwood AA, Goulden N,  Impact of PTEN abnormalities on outcome in pediatric patients with T-cell acute lymphoblastic leukemia treated on the MRC UKALL2003 trial. Leukemia 2016;30:39\u201347."},{"key":"B50","series-title":"Leukemia","first-page":"2014","article-title":"NOTCH1 and\/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols","volume":"24","author":"Zuurbier L","year":"2010","unstructured":"Zuurbier L, Homminga I, Calvert V,  NOTCH1 and\/or FBXW7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols. Leukemia 2010;24:2014\u20132022."},{"key":"B51","series-title":"Nature","first-page":"1082","article-title":"The genomic basis of childhood T-lineage acute lymphoblastic leukaemia","volume":"632","author":"Polonen P","year":"2024","unstructured":"Polonen P, Di Giacomo D, Seffernick AE,  The genomic basis of childhood T-lineage acute lymphoblastic leukaemia. Nature 2024;632:1082\u20131091."},{"key":"B52","series-title":"Lancet Oncol","first-page":"e57","article-title":"Fertility preservation for male patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"22","author":"Mulder RL","year":"2021","unstructured":"Mulder RL, Font-Gonzalez A, Green DM,  Fertility preservation for male patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 2021;22:e57\u201367."},{"key":"B53","series-title":"Lancet Oncol","first-page":"e45","article-title":"Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"22","author":"Mulder RL","year":"2021","unstructured":"Mulder RL, Font-Gonzalez A, Hudson MM,  Fertility preservation for female patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 2021;22:e45\u201356."},{"key":"B54","series-title":"Nat Rev Clin Oncol","first-page":"227","article-title":"Somatic and germline genomics in paediatric acute lymphoblastic leukaemia","volume":"16","author":"Pui CH","year":"2019","unstructured":"Pui CH, Nichols KE, Yang JJ. Somatic and germline genomics in paediatric acute lymphoblastic leukaemia. Nat Rev Clin Oncol 2019;16:227\u2013240."},{"key":"B55","series-title":"Lancet","first-page":"165","article-title":"Risks of leukaemia and solid tumours in individuals with Down\u2019s syndrome","volume":"355","author":"Hasle H","year":"2000","unstructured":"Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down\u2019s syndrome. Lancet 2000;355:165\u2013169."},{"key":"B56","series-title":"Nat Genet","first-page":"242","article-title":"The genomic landscape of hypodiploid acute lymphoblastic leukemia","volume":"45","author":"Holmfeldt L","year":"2013","unstructured":"Holmfeldt L, Wei L, Diaz-Flores E,  The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 2013;45:242\u2013252."},{"key":"B57","series-title":"J Clin Oncol","first-page":"156","article-title":"Acute lymphoblastic leukemia occurring as a second malignant neoplasm in childhood: report of three cases and review of the literature","volume":"10","author":"Hunger SP","year":"1992","unstructured":"Hunger SP, Sklar J, Link MP. Acute lymphoblastic leukemia occurring as a second malignant neoplasm in childhood: report of three cases and review of the literature. J Clin Oncol 1992;10:156\u2013163."},{"key":"B58","series-title":"Lancet Oncol","first-page":"1677","article-title":"Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial","volume":"16","author":"Place AE","year":"2015","unstructured":"Place AE, Stevenson KE, Vrooman LM,  Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncol 2015;16:1677\u20131690."},{"key":"B59","series-title":"J Clin Oncol","first-page":"2926","article-title":"Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children\u2019s Oncology Group AALL0434 Methotrexate Randomization","volume":"36","author":"Winter SS","year":"2018","unstructured":"Winter SS, Dunsmore KP, Devidas M,  Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: results from the Children\u2019s Oncology Group AALL0434 Methotrexate Randomization. J Clin Oncol 2018;36:2926\u20132934."},{"key":"B60","series-title":"J Clin Oncol","first-page":"377","article-title":"Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group","volume":"27","author":"Bader P","year":"2009","unstructured":"Bader P, Kreyenberg H, Henze GH,  Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Oncol 2009;27:377\u2013384."},{"key":"B61","series-title":"N Engl J Med","first-page":"591","article-title":"Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer\u2013Childhood Leukemia Cooperative Group","volume":"339","author":"Cave H","year":"1998","unstructured":"Cave H, van der Werff ten Bosch J, Suciu S,  Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer\u2013Childhood Leukemia Cooperative Group. N Engl J Med 1998;339:591\u2013598."},{"key":"B62","series-title":"Blood","first-page":"5477","article-title":"Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children\u2019s Oncology Group study","volume":"111","author":"Borowitz MJ","year":"2008","unstructured":"Borowitz MJ, Devidas M, Hunger SP,  Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children\u2019s Oncology Group study. Blood 2008;111:5477\u20135485."},{"key":"B63","series-title":"Blood","first-page":"3206","article-title":"Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study","volume":"115","author":"Conter V","year":"2010","unstructured":"Conter V, Bartram CR, Valsecchi MG,  Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood 2010;115:3206\u20133214."},{"key":"B64","series-title":"Leukemia","first-page":"1648","article-title":"Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment","volume":"29","author":"Eckert C","year":"2015","unstructured":"Eckert C, Hagedorn N, Sramkova L,  Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment. Leukemia 2015;29:1648\u20131655."},{"key":"B65","series-title":"Eur J Cancer","first-page":"1346","article-title":"Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95\/96","volume":"49","author":"Eckert C","year":"2013","unstructured":"Eckert C, von Stackelberg A, Seeger K,  Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95\/96. Eur J Cancer 2013;49:1346\u20131355."},{"key":"B66","series-title":"Blood","first-page":"2077","article-title":"Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study","volume":"118","author":"Schrappe M","year":"2011","unstructured":"Schrappe M, Valsecchi MG, Bartram CR,  Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood 2011;118:2077\u20132084."},{"key":"B67","series-title":"Leukemia","first-page":"1073","article-title":"Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol","volume":"23","author":"Van der Velden VH","year":"2009","unstructured":"Van der Velden VH, Corral L, Valsecchi MG,  Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol. Leukemia 2009;23:1073\u20131079."},{"key":"B68","series-title":"Blood","first-page":"1","article-title":"lymphoblastic leukemia (T-ALL) shows excellent outcome, lack of significance of the early thymic precursor (ETP) immunophenotype, and validation of the prognostic value of end-induction minimal residual disease (MRD) in Children\u2019s Oncology Group (COG) Study AALL0434","volume":"124","author":"Wood BL","year":"2014","unstructured":"Wood BL, Winter SS, Dunsmore KP, -lymphoblastic leukemia (T-ALL) shows excellent outcome, lack of significance of the early thymic precursor (ETP) immunophenotype, and validation of the prognostic value of end-induction minimal residual disease (MRD) in Children\u2019s Oncology Group (COG) Study AALL0434. Blood 2014;124:1."},{"key":"B69","series-title":"JAMA Oncol","first-page":"e170580","article-title":"Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis","volume":"3","author":"Berry DA","year":"2017","unstructured":"Berry DA, Zhou S, Higley H,  Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol 2017;3:e170580."},{"key":"B70","series-title":"Nat Commun","first-page":"2680","article-title":"Using synthetic templates to design an unbiased multiplex PCR assay","volume":"4","author":"Carlson CS","year":"2013","unstructured":"Carlson CS, Emerson RO, Sherwood AM,  Using synthetic templates to design an unbiased multiplex PCR assay. Nat Commun 2013;4:2680."},{"key":"B71","series-title":"Leukemia","first-page":"635","article-title":"Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia","volume":"27","author":"Denys B","year":"2013","unstructured":"Denys B, van der Sluijs-Gelling AJ, Homburg C,  Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia 2013;27:635\u2013641."},{"key":"B72","series-title":"Blood","first-page":"5173","article-title":"Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia","volume":"120","author":"Faham M","year":"2012","unstructured":"Faham M, Zheng J, Moorhead M,  Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood 2012;120:5173\u20135180."},{"key":"B73","series-title":"Haematologica","first-page":"1582","article-title":"Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia","volume":"97","author":"Gaipa G","year":"2012","unstructured":"Gaipa G, Cazzaniga G, Valsecchi MG,  Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia. Haematologica 2012;97:1582\u20131593."},{"key":"B74","series-title":"Leukemia","first-page":"1299","article-title":"Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders","volume":"28","author":"Ladetto M","year":"2014","unstructured":"Ladetto M, Bruggemann M, Monitillo L,  Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. Leukemia 2014;28:1299\u20131307."},{"key":"B75","series-title":"Blood","first-page":"4657","article-title":"Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia","volume":"115","author":"Stow P","year":"2010","unstructured":"Stow P, Key L, Chen X,  Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. Blood 2010;115:4657\u20134663."},{"key":"B76","series-title":"Blood","first-page":"1350","article-title":"Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL","volume":"131","author":"Wood B","year":"2018","unstructured":"Wood B, Wu D, Crossley B,  Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. Blood 2018;131:1350\u20131359."},{"key":"B77","series-title":"Am J Clin Pathol","first-page":"38","article-title":"How I diagnose minimal\/measurable residual disease in B lymphoblastic leukemia\/lymphoma by flow cytometry","volume":"155","author":"Cherian S","year":"2021","unstructured":"Cherian S, Soma LA. How I diagnose minimal\/measurable residual disease in B lymphoblastic leukemia\/lymphoma by flow cytometry. Am J Clin Pathol 2021;155:38\u201354."},{"key":"B78","series-title":"Hematology Am Soc Hematol Educ Program","first-page":"7","article-title":"Minimal residual disease in acute lymphoblastic leukemia","volume":"2010","author":"Campana D.","year":"2010","unstructured":"Campana D. Minimal residual disease in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2010;2010:7\u201312."},{"key":"B79","series-title":"Leukemia","first-page":"521","article-title":"Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18\u201320 September 2008","volume":"24","author":"Bruggemann M","year":"2010","unstructured":"Bruggemann M, Schrauder A, Raff T,  Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18\u201320 September 2008. Leukemia 2010;24:521\u2013535."},{"key":"B80","series-title":"Leukemia","first-page":"934","article-title":"Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia","volume":"18","author":"Neale GA","year":"2004","unstructured":"Neale GA, Coustan-Smith E, Stow P,  Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia 2004;18:934\u2013938."},{"key":"B81","series-title":"Clin Cancer Res","first-page":"4540","article-title":"Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH","volume":"20","author":"Wu D","year":"2014","unstructured":"Wu D, Emerson RO, Sherwood A,  Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH. Clin Cancer Res 2014;20:4540\u20134548."},{"key":"B82","series-title":"Sci Transl Med","first-page":"134ra63","article-title":"High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia","volume":"4","author":"Wu D","year":"2012","unstructured":"Wu D, Sherwood A, Fromm JR,  High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia. Sci Transl Med 2012;4:134ra63."},{"key":"B83","series-title":"Br J Haematol","first-page":"774","article-title":"Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR","volume":"128","author":"Kerst G","year":"2005","unstructured":"Kerst G, Kreyenberg H, Roth C,  Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR. Br J Haematol 2005;128:774\u2013782."},{"key":"B84","series-title":"Lancet","first-page":"550","article-title":"Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia","volume":"351","author":"Coustan-Smith E","year":"1998","unstructured":"Coustan-Smith E, Behm FG, Sanchez J,  Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 1998;351:550\u2013554."},{"key":"B85","series-title":"Blood","first-page":"2691","article-title":"Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia","volume":"96","author":"Coustan-Smith E","year":"2000","unstructured":"Coustan-Smith E, Sancho J, Hancock ML,  Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 2000;96:2691\u20132696."},{"key":"B86","series-title":"Blood","first-page":"52","article-title":"Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia","volume":"100","author":"Coustan-Smith E","year":"2002","unstructured":"Coustan-Smith E, Sancho J, Behm FG,  Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia. Blood 2002;100:52\u201358."},{"key":"B87","series-title":"J Clin Oncol","first-page":"34","article-title":"Genotype-specific minimal residual disease interpretation improves stratification in pediatric acute lymphoblastic leukemia","volume":"36","author":"O\u2019Connor D","year":"2018","unstructured":"O\u2019Connor D, Enshaei A, Bartram J,  Genotype-specific minimal residual disease interpretation improves stratification in pediatric acute lymphoblastic leukemia. J Clin Oncol 2018;36:34\u201343."},{"key":"B88","series-title":"J Clin Oncol","first-page":"3533","article-title":"Minimal disseminated disease in childhood T-cell lymphoblastic lymphoma: a report from the children\u2019s oncology group","volume":"27","author":"Coustan-Smith E","year":"2009","unstructured":"Coustan-Smith E, Sandlund JT, Perkins SL,  Minimal disseminated disease in childhood T-cell lymphoblastic lymphoma: a report from the children\u2019s oncology group. J Clin Oncol 2009;27:3533\u20133539."},{"key":"B89","series-title":"J Clin Oncol","first-page":"3062","article-title":"Successful outcomes of newly diagnosed T lymphoblastic lymphoma: results from Children\u2019s Oncology Group AALL0434","volume":"38","author":"Hayashi RJ","year":"2020","unstructured":"Hayashi RJ, Winter SS, Dunsmore KP,  Successful outcomes of newly diagnosed T lymphoblastic lymphoma: results from Children\u2019s Oncology Group AALL0434. J Clin Oncol 2020;38:3062\u20133070."},{"key":"B90","series-title":"Blood","first-page":"2053","article-title":"MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children\u2019s Oncology Group trial AALL1231","volume":"143","author":"Hayashi RJ","year":"2024","unstructured":"Hayashi RJ, Hermiston ML, Wood BL,  MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children\u2019s Oncology Group trial AALL1231. Blood 2024;143:2053\u20132058."},{"key":"B91","series-title":"J Clin Oncol","first-page":"648","article-title":"Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study","volume":"28","author":"Ko RH","year":"2010","unstructured":"Ko RH, Ji L, Barnette P,  Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. J Clin Oncol 2010;28:648\u2013654."},{"key":"B92","series-title":"Leukemia","first-page":"499","article-title":"Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse","volume":"18","author":"Coustan-Smith E","year":"2004","unstructured":"Coustan-Smith E, Gajjar A, Hijiya N,  Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse. Leukemia 2004;18:499\u2013504."},{"key":"B93","series-title":"J Clin Oncol","first-page":"3553","article-title":"Postinduction minimal residual disease monitoring by polymerase chain reaction in children with acute lymphoblastic leukemia","volume":"32","author":"Paganin M","year":"2014","unstructured":"Paganin M, Fabbri G, Conter V,  Postinduction minimal residual disease monitoring by polymerase chain reaction in children with acute lymphoblastic leukemia. J Clin Oncol 2014;32:3553\u20133558."},{"key":"B94","series-title":"Leukemia","first-page":"2193","article-title":"Minimal residual disease is an important predictive factor of outcome in children with relapsed \u2018high-risk\u2019 acute lymphoblastic leukemia","volume":"22","author":"Paganin M","year":"2008","unstructured":"Paganin M, Zecca M, Fabbri G,  Minimal residual disease is an important predictive factor of outcome in children with relapsed \u2018high-risk\u2019 acute lymphoblastic leukemia. Leukemia 2008;22:2193\u20132200."},{"key":"B95","series-title":"J Clin Oncol","first-page":"5168","article-title":"Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow","volume":"27","author":"Basso G","year":"2009","unstructured":"Basso G, Veltroni M, Valsecchi MG,  Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol 2009;27:5168\u20135174."},{"key":"B96","series-title":"Blood","first-page":"790","article-title":"Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia","volume":"95","author":"Panzer-Grumayer ER","year":"2000","unstructured":"Panzer-Grumayer ER, Schneider M, Panzer S,  Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood 2000;95:790\u2013794."},{"key":"B97","series-title":"Blood","first-page":"964","article-title":"Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children\u2019s Oncology Group study AALL0232","volume":"126","author":"Borowitz MJ","year":"2015","unstructured":"Borowitz MJ, Wood BL, Devidas M,  Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children\u2019s Oncology Group study AALL0232. Blood 2015;126:964\u2013971."},{"key":"B98","series-title":"Blood Cancer Discov","first-page":"66","article-title":"Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia","volume":"3","author":"Pulsipher MA","year":"2022","unstructured":"Pulsipher MA, Han X, Maude SL,  Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia. Blood Cancer Discov 2022;3:66\u201381."},{"key":"B99","series-title":"Lancet","first-page":"1943","article-title":"Acute lymphoblastic leukaemia","volume":"381","author":"Inaba H","year":"2013","unstructured":"Inaba H, Greaves M, Mullighan CG. Acute lymphoblastic leukaemia. Lancet 2013;381:1943\u20131955."},{"key":"B100","series-title":"Hematology Am Soc Hematol Educ Program","first-page":"374","article-title":"Treatment of acute lymphoblastic leukemia in children and adolescents: peaks and pitfalls","author":"Seibel NL.","year":"2008","unstructured":"Seibel NL. Treatment of acute lymphoblastic leukemia in children and adolescents: peaks and pitfalls. Hematology Am Soc Hematol Educ Program 2008:374\u2013380."},{"key":"B101","series-title":"Leukemia","first-page":"1099","article-title":"BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996)","volume":"16","author":"Kamps WA","year":"2002","unstructured":"Kamps WA, Bokkerink JP, Hakvoort-Cammel FG,  BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996). Leukemia 2002;16:1099\u20131111."},{"key":"B102","series-title":"Blood","first-page":"4477","article-title":"Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95","volume":"111","author":"Moricke A","year":"2008","unstructured":"Moricke A, Reiter A, Zimmermann M,  Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008;111:4477\u20134489."},{"key":"B103","series-title":"Blood","first-page":"3310","article-title":"Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group","volume":"95","author":"Schrappe M","year":"2000","unstructured":"Schrappe M, Reiter A, Ludwig WD,  Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 2000;95:3310\u20133322."},{"key":"B104","series-title":"Blood","first-page":"2548","article-title":"Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group","volume":"111","author":"Seibel NL","year":"2008","unstructured":"Seibel NL, Steinherz PG, Sather HN,  Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group. Blood 2008;111:2548\u20132555."},{"key":"B105","series-title":"Blood","first-page":"1646","article-title":"What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children\u2019s Cancer Group and Cancer and Leukemia Group B studies","volume":"112","author":"Stock W","year":"2008","unstructured":"Stock W, La M, Sanford B,  What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children\u2019s Cancer Group and Cancer and Leukemia Group B studies. Blood 2008;112:1646\u20131654."},{"key":"B106","series-title":"Blood","first-page":"2025","article-title":"A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811","volume":"85","author":"Larson RA","year":"1995","unstructured":"Larson RA, Dodge RK, Burns CP,  A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 1995;85:2025\u20132037."},{"key":"B107","series-title":"Blood","first-page":"3809","article-title":"Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children\u2019s Cancer Group","volume":"101","author":"Bostrom BC","year":"2003","unstructured":"Bostrom BC, Sensel MR, Sather HN,  Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children\u2019s Cancer Group. Blood 2003;101:3809\u20133817."},{"key":"B108","series-title":"Br J Haematol","first-page":"734","article-title":"Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial","volume":"129","author":"Mitchell CD","year":"2005","unstructured":"Mitchell CD, Richards SM, Kinsey SE,  Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial. Br J Haematol 2005;129:734\u2013745."},{"key":"B109","series-title":"Hematology Am Soc Hematol Educ Program","first-page":"142","article-title":"Central nervous system disease in acute lymphoblastic leukemia: prophylaxis and treatment","author":"Pui CH.","year":"2006","unstructured":"Pui CH. Central nervous system disease in acute lymphoblastic leukemia: prophylaxis and treatment. Hematology Am Soc Hematol Educ Program 2006:142\u2013146."},{"key":"B110","series-title":"Blood","first-page":"2101","article-title":"Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000","volume":"127","author":"Moricke A","year":"2016","unstructured":"Moricke A, Zimmermann M, Valsecchi MG,  Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. Blood 2016;127:2101\u20132112."},{"key":"B111","series-title":"Leukemia","first-page":"1232","article-title":"Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis","volume":"25","author":"Teuffel O","year":"2011","unstructured":"Teuffel O, Kuster SP, Hunger SP,  Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis. Leukemia 2011;25:1232\u20131238."},{"key":"B112","series-title":"Blood","first-page":"1986","article-title":"A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children\u2019s Cancer Group study","volume":"99","author":"Avramis VI","year":"2002","unstructured":"Avramis VI, Sencer S, Periclou AP,  A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children\u2019s Cancer Group study. Blood 2002;99:1986\u20131994."},{"key":"B113","series-title":"J Clin Oncol","first-page":"3496","article-title":"Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic leukemia: results of DFCI 11-001","volume":"39","author":"Vrooman LM","year":"2021","unstructured":"Vrooman LM, Blonquist TM, Stevenson KE,  Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic leukemia: results of DFCI 11-001. J Clin Oncol 2021;39:3496\u20133505."},{"key":"B114","series-title":"Leuk Lymphoma","first-page":"776","article-title":"Asparaginase therapy in patients with acute lymphoblastic leukemia: expert opinion on use and toxicity management","volume":"64","author":"Sandley M","year":"2023","unstructured":"Sandley M, Angus J. Asparaginase therapy in patients with acute lymphoblastic leukemia: expert opinion on use and toxicity management. Leuk Lymphoma 2023;64:776\u2013787."},{"key":"B115","series-title":"Blood","first-page":"704","article-title":"Recombinant erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2\/3 AALL1931 study","volume":"141","author":"Maese L","year":"2023","unstructured":"Maese L, Loh ML, Choi MR,  Recombinant erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2\/3 AALL1931 study. Blood 2023;141:704\u2013712."},{"key":"B116","article-title":"FDA approves a new dosing regimen for asparaginase erwinia chrysanthemi (recombinant)","unstructured":"U.S. Food and Drug Administration. FDA approves a new dosing regimen for asparaginase erwinia chrysanthemi (recombinant). Accessed August 4, 2023. Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-new-dosing-regimen-asparaginase-erwinia-chrysanthemi-recombinant"},{"key":"B117","article-title":"A study to investigate blinatumomab in combination with chemotherapy in patients with newly diagnosed B-lymphoblastic leukemia","unstructured":"ClinicalTrials.gov. A study to investigate blinatumomab in combination with chemotherapy in patients with newly diagnosed B-lymphoblastic leukemia. Accessed January 29, 2024. Available at: https:\/\/clinicaltrials.gov\/study\/NCT03914625"},{"key":"B118","series-title":"J Clin Oncol","first-page":"1437","article-title":"Excellent outcomes with reduced frequency of vincristine and dexamethasone pulses in standard-risk B-lymphoblastic leukemia: results from Children\u2019s Oncology Group AALL0932","volume":"39","author":"Angiolillo AL","year":"2021","unstructured":"Angiolillo AL, Schore RJ, Kairalla JA,  Excellent outcomes with reduced frequency of vincristine and dexamethasone pulses in standard-risk B-lymphoblastic leukemia: results from Children\u2019s Oncology Group AALL0932. J Clin Oncol 2021;39:1437\u20131447."},{"key":"B119","article-title":"Inotuzumab ozogamicin and post-induction chemotherapy in treating patients with high-risk B-all, mixed phenotype acute leukemia, and B-LLy","unstructured":"ClinicalTrials.gov. Inotuzumab ozogamicin and post-induction chemotherapy in treating patients with high-risk B-all, mixed phenotype acute leukemia, and B-LLy. Accessed January 29, 2024. Available at: https:\/\/www.clinicaltrials.gov\/study\/NCT03959085"},{"key":"B120","series-title":"Haematologica","first-page":"986","article-title":"Replacing cyclophosphamide\/cytarabine\/mercaptopurine with cyclophosphamide\/etoposide during consolidation\/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG","volume":"104","author":"Burke MJ","year":"2019","unstructured":"Burke MJ, Salzer WL, Devidas M,  Replacing cyclophosphamide\/cytarabine\/mercaptopurine with cyclophosphamide\/etoposide during consolidation\/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG. Haematologica 2019;104:986\u2013992."},{"key":"B121","series-title":"Blood","first-page":"555","article-title":"A phase 2 study of ruxolitinib with chemotherapy in children with Philadelphia chromosome-like acute lymphoblastic leukemia (INCB18424-269\/AALL1521): dose-finding results from the Part 1 safety phase","volume":"132","author":"Tasian SK","year":"2018","unstructured":"Tasian SK, Assad A, Hunter DS,  A phase 2 study of ruxolitinib with chemotherapy in children with Philadelphia chromosome-like acute lymphoblastic leukemia (INCB18424-269\/AALL1521): dose-finding results from the Part 1 safety phase. Blood 2018;132:555."},{"key":"B122","series-title":"J Clin Oncol","first-page":"2106","article-title":"Children\u2019s Oncology Group trial AALL1231: A phase III clinical trial testing bortezomib in newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma","volume":"40","author":"Teachey DT","year":"2022","unstructured":"Teachey DT, Devidas M, Wood BL,  Children\u2019s Oncology Group trial AALL1231: A phase III clinical trial testing bortezomib in newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma. J Clin Oncol 2022;40:2106\u20132118."},{"key":"B123","series-title":"Pediatr Blood Cancer","first-page":"1176","article-title":"Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children\u2019s Oncology Group Study AALL0434","volume":"62","author":"Winter SS","year":"2015","unstructured":"Winter SS, Dunsmore KP, Devidas M,  Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children\u2019s Oncology Group Study AALL0434. Pediatr Blood Cancer 2015;62:1176\u20131183."},{"key":"B124","article-title":"Imatinib mesylate and combination chemotherapy in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia","unstructured":"ClinicalTrials.gov. Imatinib mesylate and combination chemotherapy in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. Accessed January 29, 2024. Available at: https:\/\/clinicaltrials.gov\/study\/NCT03007147"},{"key":"B125","article-title":"Azacitidine and combination chemotherapy in treating infants with acute lymphoblastic leukemia and KMT2A gene rearrangement","unstructured":"ClinicalTrials.gov. Azacitidine and combination chemotherapy in treating infants with acute lymphoblastic leukemia and KMT2A gene rearrangement. Accessed January 29, 2024. Available at: https:\/\/www.clinicaltrials.gov\/study\/NCT02828358"},{"key":"B126","series-title":"Lancet Haematol","first-page":"e510","article-title":"Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372\/COG AALL1122): a single-arm, multicentre, phase 2 trial","volume":"10","author":"Hunger SP","year":"2023","unstructured":"Hunger SP, Tran TH, Saha V,  Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372\/COG AALL1122): a single-arm, multicentre, phase 2 trial. Lancet Haematol 2023;10:e510\u2013520."},{"key":"B127","series-title":"Eur J Pharm Sci","first-page":"329","article-title":"Metabolites of mercaptopurine in red blood cells: a relationship between 6-thioguanine nucleotides and 6-methylmercaptopurine metabolite concentrations in children with lymphoblastic leukemia","volume":"8","author":"Chrzanowska M","year":"1999","unstructured":"Chrzanowska M, Kolecki P, Duczmal-Cichocka B, Fiet J. Metabolites of mercaptopurine in red blood cells: a relationship between 6-thioguanine nucleotides and 6-methylmercaptopurine metabolite concentrations in children with lymphoblastic leukemia. Eur J Pharm Sci 1999;8:329\u2013334."},{"key":"B128","series-title":"J Clin Oncol","first-page":"1816","article-title":"Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia","volume":"7","author":"Lennard L","year":"1989","unstructured":"Lennard L, Lilleyman JS. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol 1989;7:1816\u20131823."},{"key":"B129","series-title":"Br J Clin Pharmacol","first-page":"826","article-title":"Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia","volume":"66","author":"Hawwa AF","year":"2008","unstructured":"Hawwa AF, Collier PS, Millership JS,  Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia. Br J Clin Pharmacol 2008;66:826\u2013837."},{"key":"B130","series-title":"Br J Haematol","first-page":"696","article-title":"Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia","volume":"105","author":"McLeod HL","year":"1999","unstructured":"McLeod HL, Coulthard S, Thomas AE,  Analysis of thiopurine methyltransferase variant alleles in childhood acute lymphoblastic leukaemia. Br J Haematol 1999;105:696\u2013700."},{"key":"B131","series-title":"Br J Cancer Suppl","first-page":"S23","article-title":"Disposition of antineoplastic agents in the very young child","volume":"18","author":"McLeod HL","year":"1992","unstructured":"McLeod HL, Relling MV, Crom WR,  Disposition of antineoplastic agents in the very young child. Br J Cancer Suppl 1992;18:S23\u201329."},{"key":"B132","series-title":"Pharmacogenetics","first-page":"37","article-title":"The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations","volume":"9","author":"Collie-Duguid ES","year":"1999","unstructured":"Collie-Duguid ES, Pritchard SC, Powrie RH,  The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 1999;9:37\u201342."},{"key":"B133","series-title":"Clin Pharmacol Ther","first-page":"15","article-title":"Thiopurine methyltransferase activity in American white subjects and black subjects","volume":"55","author":"McLeod HL","year":"1994","unstructured":"McLeod HL, Lin JS, Scott EP,  Thiopurine methyltransferase activity in American white subjects and black subjects. Clin Pharmacol Ther 1994;55:15\u201320."},{"key":"B134","series-title":"Am J Hum Genet","first-page":"651","article-title":"Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity","volume":"32","author":"Weinshilboum RM","year":"1980","unstructured":"Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980;32:651\u2013662."},{"key":"B135","series-title":"Clin Pharmacol Ther","first-page":"1095","article-title":"Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update","volume":"105","author":"Relling MV","year":"2019","unstructured":"Relling MV, Schwab M, Whirl-Carrillo M,  Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update. Clin Pharmacol Ther 2019;105:1095\u20131105."},{"key":"B136","series-title":"J Clin Oncol","first-page":"2094","article-title":"Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children\u2019s oncology group","volume":"30","author":"Bhatia S","year":"2012","unstructured":"Bhatia S, Landier W, Shangguan M,  Nonadherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukemia: a report from the children\u2019s oncology group. J Clin Oncol 2012;30:2094\u20132101."},{"key":"B137","series-title":"Blood","first-page":"1802","article-title":"Central nervous system status is prognostic in T-cell acute lymphoblastic leukemia: a Children\u2019s Oncology Group report","volume":"141","author":"Gossai NP","year":"2023","unstructured":"Gossai NP, Devidas M, Chen Z,  Central nervous system status is prognostic in T-cell acute lymphoblastic leukemia: a Children\u2019s Oncology Group report. Blood 2023;141:1802\u20131811."},{"key":"B138","series-title":"J Clin Oncol","first-page":"2527","article-title":"Impact of initial CSF findings on outcome among patients with National Cancer Institute standard- and high-risk B-cell acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group","volume":"35","author":"Winick N","year":"2017","unstructured":"Winick N, Devidas M, Chen S,  Impact of initial CSF findings on outcome among patients with National Cancer Institute standard- and high-risk B-cell acute lymphoblastic leukemia: a report from the Children\u2019s Oncology Group. J Clin Oncol 2017;35:2527\u20132534."},{"key":"B139","series-title":"Pediatr Blood Cancer","first-page":"185","article-title":"Systematic review and meta-analysis of randomized trials of central nervous system directed therapy for childhood acute lymphoblastic leukemia","volume":"60","author":"Richards S","year":"2013","unstructured":"Richards S, Pui CH, Gayon P. Systematic review and meta-analysis of randomized trials of central nervous system directed therapy for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2013;60:185\u2013195."},{"key":"B140","series-title":"Lancet","first-page":"635","article-title":"Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study","volume":"366","author":"Balduzzi A","year":"2005","unstructured":"Balduzzi A, Valsecchi MG, Uderzo C,  Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study. Lancet 2005;366:635\u2013642."},{"key":"B141","series-title":"Blood","first-page":"223","article-title":"High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia","volume":"118","author":"Leung W","year":"2011","unstructured":"Leung W, Campana D, Yang J,  High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia. Blood 2011;118:223\u2013230."},{"key":"B142","series-title":"Lancet","first-page":"1947","article-title":"Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study","volume":"369","author":"Eapen M","year":"2007","unstructured":"Eapen M, Rubinstein P, Zhang MJ,  Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet 2007;369:1947\u20131954."},{"key":"B143","series-title":"J Clin Oncol","first-page":"295","article-title":"Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study","volume":"39","author":"Peters C","year":"2021","unstructured":"Peters C, Dalle JH, Locatelli F,  Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study. J Clin Oncol 2021;39:295\u2013307."},{"key":"B144","series-title":"J Clin Oncol","first-page":"340","article-title":"Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia","volume":"18","author":"Davies SM","year":"2000","unstructured":"Davies SM, Ramsay NK, Klein JP,  Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol 2000;18:340\u2013347."},{"key":"B145","series-title":"Bone Marrow Transplant","first-page":"543","article-title":"Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study","volume":"32","author":"Bunin N","year":"2003","unstructured":"Bunin N, Aplenc R, Kamani N,  Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study. Bone Marrow Transplant 2003;32:543\u2013548."},{"key":"B146","series-title":"J Clin Oncol","first-page":"3376","article-title":"Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children\u2019s Oncology Group","volume":"23","author":"Berg SL","year":"2005","unstructured":"Berg SL, Blaney SM, Devidas M,  Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children\u2019s Oncology Group. J Clin Oncol 2005;23:3376\u20133382."},{"key":"B147","series-title":"J Clin Oncol","first-page":"3282","article-title":"Children\u2019s Oncology Group AALL0434: a phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia","volume":"38","author":"Dunsmore KP","year":"2020","unstructured":"Dunsmore KP, Winter SS, Devidas M,  Children\u2019s Oncology Group AALL0434: a phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia. J Clin Oncol 2020;38:3282\u20133293."},{"key":"B148","series-title":"Pediatr Blood Cancer","first-page":"e28719","article-title":"Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: results from DFCI ALL Consortium Protocols 05-001 and 11-001","volume":"68","author":"Burns MA","year":"2021","unstructured":"Burns MA, Place AE, Stevenson KE,  Identification of prognostic factors in childhood T-cell acute lymphoblastic leukemia: results from DFCI ALL Consortium Protocols 05-001 and 11-001. Pediatr Blood Cancer 2021;68:e28719."},{"key":"B149","series-title":"J Clin Oncol","first-page":"5742","article-title":"Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95","volume":"24","author":"Schrauder A","year":"2006","unstructured":"Schrauder A, Reiter A, Gadner H,  Superiority of allogeneic hematopoietic stem-cell transplantation compared with chemotherapy alone in high-risk childhood T-cell acute lymphoblastic leukemia: results from ALL-BFM 90 and 95. J Clin Oncol 2006;24:5742\u20135749."},{"key":"B150","series-title":"Blood","first-page":"5136","article-title":"Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801","volume":"109","author":"DeAngelo DJ","year":"2007","unstructured":"DeAngelo DJ, Yu D, Johnson JL,  Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood 2007;109:5136\u20135142."},{"key":"B151","series-title":"Pediatr Blood Cancer","first-page":"e29901","article-title":"Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008-002 NECTAR)","volume":"69","author":"Whitlock JA","year":"2022","unstructured":"Whitlock JA, Malvar J, Dalla-Pozza L,  Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008-002 NECTAR). Pediatr Blood Cancer 2022;69:e29901."},{"key":"B152","series-title":"Br J Haematol","first-page":"274","article-title":"Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children\u2019s Oncology Group","volume":"186","author":"Horton TM","year":"2019","unstructured":"Horton TM, Whitlock JA, Lu X,  Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children\u2019s Oncology Group. Br J Haematol 2019;186:274\u2013285."},{"key":"B153","series-title":"Lancet","first-page":"2009","article-title":"Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial","volume":"376","author":"Parker C","year":"2010","unstructured":"Parker C, Waters R, Leighton C,  Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet 2010;376:2009\u20132017."},{"key":"B154","series-title":"J Clin Oncol","first-page":"2339","article-title":"Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90","volume":"28","author":"Tallen G","year":"2010","unstructured":"Tallen G, Ratei R, Mann G,  Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J Clin Oncol 2010;28:2339\u20132347."},{"key":"B155","series-title":"Blood","first-page":"37","article-title":"Pediatric patients with relapsed\/refractory acute lymphoblastic leukemia harboring heterogeneous genomic profiles respond to venetoclax in combination with chemotherapy","volume":"136","author":"Place AE","year":"2020","unstructured":"Place AE, Karol SE, Forlenza CJ,  Pediatric patients with relapsed\/refractory acute lymphoblastic leukemia harboring heterogeneous genomic profiles respond to venetoclax in combination with chemotherapy. Blood 2020;136:37\u201338."},{"key":"B156","series-title":"Clin Lymphoma Myeloma Leuk","first-page":"212","article-title":"Clinical experience with venetoclax combined with chemotherapy for relapsed or refractory T-cell acute lymphoblastic leukemia","volume":"20","author":"Richard-Carpentier G","year":"2020","unstructured":"Richard-Carpentier G, Jabbour E, Short NJ,  Clinical experience with venetoclax combined with chemotherapy for relapsed or refractory T-cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 2020;20:212\u2013218."},{"key":"B157","series-title":"Blood","first-page":"2237","article-title":"Daratumumab in pediatric relapsed\/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: DELPHINUS study","volume":"144","author":"Bhatla T","year":"2024","unstructured":"Bhatla T, Hogan LM, Teachey DT,  Daratumumab in pediatric relapsed\/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: DELPHINUS study. Blood 2024;144:2237\u20132247."},{"key":"B158","series-title":"J Clin Oncol","first-page":"JCO2400826","article-title":"Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101)","author":"Issa GC","year":"2024","unstructured":"Issa GC, Aldoss I, Thirman MJ,  Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101). J Clin Oncol 2024:JCO2400826."},{"key":"B159","series-title":"J Clin Oncol","first-page":"3971","article-title":"Reinduction platform for children with first marrow relapse of acute lymphoblastic leukemia: a Children\u2019s Oncology Group study[corrected]","volume":"26","author":"Raetz EA","year":"2008","unstructured":"Raetz EA, Borowitz MJ, Devidas M,  Reinduction platform for children with first marrow relapse of acute lymphoblastic leukemia: a Children\u2019s Oncology Group study[corrected]. J Clin Oncol 2008;26:3971\u20133978."},{"key":"B160","series-title":"Eur J Cancer","first-page":"175","article-title":"Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials","volume":"151","author":"Eckert C","year":"2021","unstructured":"Eckert C, Parker C, Moorman AV,  Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials. Eur J Cancer 2021;151:175\u2013189."},{"key":"B161","series-title":"J Clin Oncol","first-page":"3377","article-title":"Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation: St Jude Total Therapy Study 16","volume":"37","author":"Jeha S","year":"2019","unstructured":"Jeha S, Pei D, Choi J,  Improved CNS control of childhood acute lymphoblastic leukemia without cranial irradiation: St Jude Total Therapy Study 16. J Clin Oncol 2019;37:3377\u20133391."},{"key":"B162","series-title":"J Clin Oncol","first-page":"10001","article-title":"Efficacy and safety of daratumumab (DARA) in pediatric and young adult patients (pts) with relapsed\/refractory T-cell acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL): Results from the phase 2 DELPHINUS study","volume":"40","author":"Hogan LE","year":"2022","unstructured":"Hogan LE, Bhatla T, Teachey DT,  Efficacy and safety of daratumumab (DARA) in pediatric and young adult patients (pts) with relapsed\/refractory T-cell acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LL): Results from the phase 2 DELPHINUS study. J Clin Oncol 2022;40:10001."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/2\/article-p41.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/2\/article-p41.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/2\/article-p41.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T16:04:26Z","timestamp":1739376266000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/2\/article-p41.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":162,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2025.0006","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]}}}